Cover Image

Use ofCYP2D6Inhibitors withCYP2D6Opioids: Association with Emergency Department Visits for Pain

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Noor Ahmed Nahid, Caitrin W. McDonough, Yu‐Jung Jenny Wei, Emily J. Cicali, Yan Gong, Roger B. Fillingim, Julie A. Johnson
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Frequency of Key Pharmacogenes CYP2C9 , CYP2C19 , CYP2D6 , and SLCO1B1 in the Yogyakarta Population: Implications for Precision Prescribing in Indonesia
by: Dwi Aris Agung Nugrahaningsih, et al.
Published: (2026)

Repeated Intake of Grapefruit Juice Inhibits CYP2B6 , CYP2C9 , CYP2C19 , and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans
by: Laura Aurinsalo, et al.
Published: (2025)

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
by: Danwei Shao, et al.
Published: (2026)

Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients
by: Samantha Medwid, et al.
Published: (2024)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
by: Simeon Rüdesheim, et al.
Published: (2025)

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
by: Katherine M. Robinson, et al.
Published: (2024)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
by: Xiaoyu Men, et al.
Published: (2024)

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
by: Ashley N. Springer, et al.
Published: (2025)

PharmVar GeneFocus: CYP4F2
by: Pablo Zubiaur, et al.
Published: (2024)

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy
by: Julio D. Duarte, et al.
Published: (2024)

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data
by: Eissa A. Jafari, et al.
Published: (2025)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
by: Janne T. Backman
Published: (2025)

Correction to “Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals”
Published: (2024)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
by: Aiden‐Hung P. Nguyen, et al.
Published: (2026)

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
by: Catherine Chanfreau‐Coffinier, et al.
Published: (2025)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
by: Kenza Abouir, et al.
Published: (2024)

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
by: Yoomi Park, et al.
Published: (2026)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
by: Kenichi Umehara, et al.
Published: (2024)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
by: Yoo Jin Jang, et al.
Published: (2024)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
by: Hyun Woong Park, et al.
Published: (2025)

Age‐Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling
by: Md Masud Parvez, et al.
Published: (2024)

Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases
by: Thandeka V.B. Malinga, et al.
Published: (2025)

Impact of CYP2C19 Genotype on Sertraline and Escitalopram Exposure and Antidepressant Switching Rate: A Retrospective Cohort Study of Chinese Han Patients
by: Yuhang Yan, et al.
Published: (2025)

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
by: Amita Datta‐Mannan, et al.
Published: (2024)

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients
by: Amar D. Levens, et al.
Published: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
by: Peile Wang, et al.
Published: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
by: Yi‐An Bi, et al.
Published: (2024)

Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling
by: Friederike Kanefendt, et al.
Published: (2024)

Impaired Drug Metabolism Caused by Compound Heterozygous Loss‐of‐Function Variants in CYP3A4: A Case Report
by: Han Byul Kang, et al.
Published: (2025)

Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine
by: Jie En Valerie Sia, et al.
Published: (2024)

Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma
by: Keita Hirai, et al.
Published: (2024)

FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
by: Srikanth C. Nallani, et al.
Published: (2024)

The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
by: Chachrit Khunsriraksakul, et al.
Published: (2025)

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients
by: Weijie Kong, et al.
Published: (2025)

Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module
by: Bradley T. Hall, et al.
Published: (2025)

Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1‐Year Longitudinal Study
by: Marianna Piras, et al.
Published: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
by: Kuan‐Ju Lin, et al.
Published: (2025)

Risk of Opioid Overdose Associated with Concomitant Use of Methadone and Statins
by: Cheng Chen, et al.
Published: (2024)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
by: Lee‐Yuan Lin, et al.
Published: (2025)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
by: Maria J. Alfonso Arvez, et al.
Published: (2025)